Will Ubisoft complete a sale or merger by end of 2025?
Yes • 50%
No • 50%
Official announcements from Ubisoft or acquiring company, verified by major financial news outlets
Ubisoft Delays 'Assassin's Creed Shadows' to March 20 Amid Strategic Review and Potential Sale
Jan 9, 2025, 05:02 PM
Ubisoft has announced another delay for the release of 'Assassin's Creed Shadows,' pushing the launch date from February 14 to March 20. The company stated that the additional time will allow the development team to better incorporate player feedback and create optimal launch conditions by engaging with the Assassin's Creed community. This delay coincides with Ubisoft's strategic review and exploration of potential sale options, as the company aims to enhance operational efficiency and maximize value creation. Ubisoft has appointed leading advisors to assess various strategic and capitalistic options, a process overseen by the independent members of the Board of Directors. Yves Guillemot, Ubisoft's Co-Founder and CEO, mentioned in a strategic update that the company is confident these steps will position Ubisoft for a stronger future.
View original story
Ubisoft taken private without majority change • 25%
Tencent acquires majority stake • 25%
Another company acquires majority stake • 25%
No change in ownership structure • 25%
Deal completed with Tencent • 25%
Other outcome • 25%
No deal completed • 25%
Deal completed with another company • 25%
No change in control • 25%
Tencent gains control • 25%
Guillemot family retains control • 25%
Other entity gains control • 25%
Another entity gains control • 25%
No change in control • 25%
Tencent gains control • 25%
Guillemot family maintains control • 25%
No significant partnership or acquisition • 25%
Partnership with Tencent • 25%
Acquisition of another gaming company • 25%
Partnership with another tech company • 25%
No • 50%
Yes • 50%
Decrease by up to 10% • 25%
Increase by more than 10% • 25%
Decrease by more than 10% • 25%
Increase by up to 10% • 25%
Negative (below 50) • 25%
Mixed (50-69) • 25%
Highly positive (above 85) • 25%
Moderately positive (70-85) • 25%